Navigation Links
Genta Incorporated Announces Third Quarter 2007 Financial Results
Date:11/7/2007

greatest benefit in a preceding randomized trial. AGENDA will enroll patients using a biomarker that has been confirmed as a powerful indicator of outcome. The trial will enroll approximately 300 patients at sites in North America, Europe and Australia. More information about AGENDA can be accessed at: http://www.genta.com/index.php?option=com_content&task=view&id=38&Itemid=55 .

Initial clinical trial for G4544 opens: a new oral drug for bone disease

G4544 is a new tablet formulation using delivery technology developed by Emisphere Technologies, Inc. that enables oral absorption of the active ingredient contained in Ganite. This compound is a highly potent inhibitor of bone loss. Diseases associated with accelerated bone loss include hypercalcemia, bone metastases, Paget's disease and osteoporosis. The first clinical trial of G4544 began in normal volunteers during the 3rd quarter. Genta currently intends to manage the clinical development process of oncology indications for G4544 and to seek a development and commercial partner for non-malignant metabolic bone diseases.

FDA appeal filed for use of Genasense in chronic lymphocytic leukemia (CLL)

Following FDA's established Dispute Resolution Process, Genta filed a formal request that FDA's Center for Drug Evaluation and Research review and overturn the previous non-approvable decision for Genasense in patients with relapsed or refractory CLL. An oral hearing on the matter has been scheduled for the 4th quarter 2007.

"Named-Patient" Program Ships Initial Supplies of Genasense(R)

In parallel with the AGENDA trial, Genta has established a program that will provide Genasense on a named patient/compassionate-use basis outside the U.S. Via collaboration with IDIS, a U.K.-based company, Genta distributes drug upon request for specific patients, and revenue from the first Genasense ship
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Massachusetts , 21. Mai 2013 /PRNewswire/ ... („OSI"), die die Firmen OMNIlife science® Inc., Enztec ... zählt, hat zwei neue, erfahrene Mitglieder in ... , eine erfahrene Führungspersönlichkeit aus der ... David Johnson , anerkannter ...
(Date:5/21/2013)... May 21, 2013  LCA-Vision Inc. (NASDAQ: LCAV ... the Lasik Plus ® brand, announces that all nominees to ... at today,s annual meeting of stockholders.  These Directors are: ... President of Bahl & Gaynor Investment Counsel , ... , Edgar F. Heizer III , ...
(Date:5/21/2013)... 21, 2013  Decision Resources, one of ... for pharmaceutical and healthcare issues, finds that ... key efficacy endpoints, including overall survival and ... influence over surveyed U.S. and European oncologists, ... HER2-negative breast cancer. The two novel emerging ...
Breaking Medicine Technology:Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2
... VILLAGE, Colo. , June 28 Recondo ... the healthcare industry, announced today the general availability of ... and disparate hospital systems, applications, software services, and databases. ... developed decades ago, hospitals have been forced to deploy ...
... 28 Reportlinker.com announces that a new market research report is available in its ... Global Melanoma Therapeutics industry , ... http://www.reportlinker.com/p0197206/Global-Melanoma-Therapeutics-industry.html , ... analyzes the worldwide markets for Melanoma Therapeutics in US$ Million. The report provides separate comprehensive ...
Cached Medicine Technology:Recondo Technology Announces Integration Initiative for US Hospital Systems 2Recondo Technology Announces Integration Initiative for US Hospital Systems 3Recondo Technology Announces Integration Initiative for US Hospital Systems 4Global Melanoma Therapeutics Industry 2Global Melanoma Therapeutics Industry 3Global Melanoma Therapeutics Industry 4Global Melanoma Therapeutics Industry 5Global Melanoma Therapeutics Industry 6Global Melanoma Therapeutics Industry 7Global Melanoma Therapeutics Industry 8Global Melanoma Therapeutics Industry 9Global Melanoma Therapeutics Industry 10Global Melanoma Therapeutics Industry 11Global Melanoma Therapeutics Industry 12
(Date:5/22/2013)... 22, 2013 In partnership with ... Surge, LLC, E-Dentists.com has launched a new SEO ... feature numerous topics of interest to dentists and ... dental health. , http://www.E-Dentists.com/Blog/ , Blogging ... marketing. In addition to addressing keyword placement and ...
(Date:5/22/2013)... May 22, 2013 Teams who focus ... improvements use the new Do-Done StepTracker whiteboard as a ... the Do-Done board to display the current status of ... production cells and departments is listed down the side ... start a project, the squares are filled with yellow ...
(Date:5/22/2013)... MA New research from Brigham and Women,s Hospital ... fibrosis, an uncommon but deadly lung disease, may be ... These findings will be presented at the American ... the New England Journal of Medicine on ... 2013 print edition., "While this variant of the MUC5B ...
(Date:5/22/2013)... John Mathews from the University of Melbourne said this ... the undoubted benefits from CT scans in diagnosing and ... the British Medical Journal today and involved ... and the International Agency for Research on Cancer in ... were very useful in providing detailed three dimensional pictures ...
(Date:5/22/2013)... 21 May 2013, Paris, France: Results from ... 2013 today question whether bivalirudin is superior ... blockade, showing similar 30-day mortality in patients ... (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)., European ... alone as an alternative to unfractionated heparin ...
Breaking Medicine News(10 mins):Health News:Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC 2Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Small increase in cancer risk following CT scans in childhood and adolescence 2Health News:Registry questions superiority of bivalirudin over heparin 2
... study has found that Hypnotherapy can be used to relieve ... ,In a small study researchers randomly divided 28 patients ... group received 12 sessions of hypnotherapy over 17 weeks while ... placebo or dummy medicine. , ,According to the BMJ, ...
... Endocrinologists (AACE) Fifteenth Annual Meeting and Clinical Congress to ... 26-30 will discuss important benefits //of vitamin D and ... ,Vitamin D has been in the new ... has been attributed to it. Recent studies have highlighted ...
... According to a large study by Boston University, Black women ... greater risk of breast cancer.// ,The study was published ... Medicine., ,This study is unique because there are previous ... and so it would benefit. ,Lead researcher Dr. Lynn ...
... Madhya Pradesh fell ill after feasting at a marriage dinner, ... police said Thursday. // ,While 65 affected people ... after first aid, a hospital spokesman said. ,Earlier, ... feast. ,While many of those admitted to hospital ...
... have found a link between diet and ALS saying ... progression of Amyotrophic Lateral Sclerosis (ALS). // The Mount ... a correlation between diet and neuronal cell death, the ... an adult-onset neurodegenerative disorder in which spinal and cortical ...
... funded the sex-swap surgery of a former sailor is now ... Bainbridge, 57, from Middleton, says she needs the ?2,500 laser ... wear sleevless dresses in the summer. ,Middleton and ... is waiting for a date for surgery at Charing Cross ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: